Coeptis Therapeutics

Historical price data

Coeptis Therapeutics is advancing a differentiated pipeline of engineered cell therapies focused on overcoming the major challenges of antigen escape and treatment accessibility in oncology. Its core technologies include SNAP-CAR, a multi-antigen targeting CAR-T platform, and DARIC, a universal, multi-donor NK cell platform. The company is progressing its lead asset, COEP-001 (SNAP-CAR CD19), into clinical development for B-cell malignancies, positioning itself in the competitive but high-potential cell therapy market. As a pre-revenue, publicly traded biotech, its strategy hinges on validating its platforms through clinical proof-of-concept to attract partnership and development capital.

Coeptis's core technologies are SNAP-CAR, a switchable, multi-antigen targeting CAR-T platform, and DARIC, a universal, multi-donor NK cell platform, both designed to overcome antigen escape and scalability challenges in cell therapy.

Coeptis competes with major commercial CAR-T players (Gilead, BMS, Novartis), a crowded field of companies developing multi-targeting and switchable CAR platforms, and well-funded allogeneic cell therapy developers (Allogene, Fate Therapeutics). Its differentiation hinges on the modular design of SNAP-CAR and the specific engineering of its DARIC-NK cells.